Andrew Levin

Andrew Levin joined RA Capital Management in 2015 and is a Partner and Managing Director on the Investment Team and spearheads a drug discovery effort that has led to the formation of several new companies.

Prior to joining RA Capital, Andrew was Vice President at H.I.G. BioVentures. Previously, he served as the Director of Pharmaceutical Sciences at the Clinton Health Access Initiative. Andrew holds a BSE in Mechanical Engineering from Princeton University, a PhD in Biomedical Engineering from the Massachusetts Institute of Technology, and an MD from Harvard Medical School.